Zydus Lifesci. Q1 FY27 Share Price & Earnings Call Analysis

Financials of Zydus Lifesci.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Zydus Lifesci.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +5,0115,1404,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,587
Expenses +3,7553,6343,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,033
Operating Profit1,2561,5051,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,554
OPM %25%29%26%24%29%34%28%26%33%32%33%26%34%
Other Income +-566215360160636857-1391557526-263
Interest2818920353225327785101130123
Depreciation179180184195205215234229238238302360508
Profit before tax4841,3281,0069471,5501,9001,2711,1841,6721,9211,6871,3531,660
Tax %28%16%22%23%21%23%29%15%25%23%27%29%19%
Net Profit +3581,1348037901,2461,4829201,0261,2441,5211,2391,0231,341
EPS in Rs2.9310.747.917.8011.7514.119.0610.1711.6414.5812.5110.3612.65

Financials of Zydus Lifesci.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +8,6519,4279,37611,90513,16614,25315,10215,26517,23719,54723,24227,148
Expenses +6,8967,0957,4749,07410,17411,45511,75811,92313,37814,16316,18318,673
Operating Profit1,7562,3321,9022,8312,9912,7983,3443,3423,8605,3847,0588,475
OPM %20%25%20%24%23%20%22%22%22%28%30%31%
Other Income +45112127111183-264-1712,581-42229350-7
Interest6853459119434216412713081166439
Depreciation2872923735395996967257137237649161,408
Profit before tax1,4462,0991,6122,3122,3821,4952,2855,0842,5854,8326,0276,621
Tax %18%8%8%24%22%21%6%10%23%20%23%24%
Net Profit +1,1881,9641,5171,8101,8991,2042,1854,6182,0923,9734,6735,124
EPS in Rs11.2418.8914.5317.3518.0611.4920.8443.8319.3738.3644.9750.09
Dividend Payout %21%17%22%20%19%30%17%6%31%8%24%2%

Financials of Zydus Lifesci.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital102102102102102102102102101101101101
Reserves4,1495,5976,8588,64210,28410,27312,89016,89717,41519,72923,85227,011
Borrowings +2,6512,4425,2075,4077,8997,9864,5844,2211,1958043,21312,496
Other Liabilities +2,1442,2082,9373,6324,9455,1156,1896,4216,8518,2019,52312,799
Total Liabilities9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68952,407
Fixed Assets +3,3523,7485,7556,48312,16412,23012,13312,25311,52112,36813,13426,639
CWIP7989511,5431,5278377427836611,2012,4232,6921,166
Investments1544164357466747658303,2881,5471,2206,4087,540
Other Assets +4,7435,2357,3719,0289,5569,74010,01911,43911,29412,82214,45617,062
Total Assets9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68952,407

Financials of Zydus Lifesci.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +9941,8941,3129191,2822,5053,2932,1042,6893,2286,7772,117
Cash from Investing Activity +-465-860-2,872-974-3,977-1,012-8351,1371,178-1,492-8,377-8,296
Cash from Financing Activity +-351-9352,316521,885-1,094-2,549-868-4,400-1,8102,0145,807
Net Cash Flow17899756-3-811399-902,373-534-75414-373
Free Cash Flow498936-1,623-1162361,6172,4461,0501,6972,3455,116-530
CFO/OP79%109%81%54%65%100%109%83%85%84%122%44%

Financials of Zydus Lifesci.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6768899811094768094976373
Inventory Days175158193211208207227245197202227282
Days Payable125154165167149151155141123125133142
Cash Conversion Cycle11871116142169150148184168175158212
Working Capital Days6-1-341710-19-6197088337
ROCE %23%28%16%18%15%11%14%13%15%22%24%21%

Continue your research

What Zydus Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd